In vitro photochemical inactivation of cell‐associated human T‐cell leukemia virus Type I and II in human platelet concentrates and plasma by use of amotosalen

Abstract

In human plasma or PLT concentrates, the retroviruses HTLV-I and -II were strongly sensitive to the PCT with 150 micromol per L amotosalen (S-59) and a 3.0 J per cm2 UVA dose. This high efficiency for photoinactivation of these retroviruses opens a possibility of improving the safety of PLTs or plasma transfusion in the future.

Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function

“…These studies showed that PCT with amotosalen and UVA light is effective against a broad range of pathogens in plasma. This finding is not surprising based on the pathogen inactivation efficacy previously demonstrated for PLTs with the same dose of amotosalen and same dose of UVA light 15‐20 . The levels of inactivation for representative viruses, bacteria, and protozoa were measured with PCT conditions developed for the commercial application of FFP.…”

A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh‐frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura

“…A photochemical treatment (PCT) system with amotosalen and ultraviolet (UV) A light pathogen inactivation of single‐donor plasma has been developed. In vitro studies of this PCT system have demonstrated broad‐spectrum inactivation of viruses, bacteria, protozoa, and contaminating donor WBCs 15‐17 . Retention of coagulation factor activity, antithrombotic proteins (protein C, protein S, and antithrombin III), and VWF‐CP activity has been demonstrated in plasma treated with this process (PCT plasma) 18,19 .…”

“…In vitro studies of this PCT system have demonstrated broad-spectrum inactivation of viruses, bacteria, protozoa, and contaminating donor WBCs. [15][16][17] Retention of coagulation factor activity, antithrombotic proteins (protein C, protein S, and antithrombin III), and VWF-CP activity has been demonstrated in plasma treated with this process (PCT plasma). 18,19 PCT plasma also can be processed into PCT CSP, 20 or cryoprecipitate, 21 with a similar coagulation profile to conventional products.…”

Quantification of Viral Inactivation by Photochemical Treatment with Amotosalen and UV A Light, Using a Novel Polymerase Chain Reaction Inhibition Method with Preamplification

“…The inactivation mechanism combines the nucleic acid-intercalating property of amotosalen with its cross-linking capabilities after UVA activation to eliminate the replicative function of treated pathogens. PCT has been shown to inactivate a broad spectrum of viruses, bacteria, parasites, and white blood cells and create safer blood-transfusion products [11,12,[14][15][16][17][18][19][20].…”